Epitalon

What it is

A synthetic linear tetrapeptide Ala-Glu-Asp-Gly (AEDG), MW 390 Da. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s–90s. Epitalon is the synthetic short-peptide pharmacophore of Epithalamin - the bovine pineal gland polypeptide extract used in early Russian gerontology trials. Khavinson's group sequenced the active fragments of Epithalamin and reduced them to the smallest molecule retaining bioactivity: AEDG.

Often called "the longevity peptide." Formulated for oral bioavailability.

What it does (mechanism)

Converges on multiple aging axes:

1. Telomerase activation + telomere elongation - Khavinson, Bondarev & Butyugov 2003 (Bull Exp Biol Med 135:590) demonstrated Epitalon induces TERT activity and elongates telomeres in human somatic cells, including telomerase-negative human fetal lung fibroblasts (602/17 line). Independently replicated 2025 (Biogerontology DOI 10.1007/s10522-025-10315-x).
2. Pineal/melatonin restoration - restores age-related decline in pineal melatonin output. In elderly humans, normalizes circadian melatonin rhythm and increases nocturnal melatonin peaks toward youthful levels (Korkushko/Lapin/Khavinson cohorts). Proposed mechanism: direct peptide-DNA interaction in pinealocytes, de-repressing age-silenced genes including AANAT (rate-limiting melatonin enzyme).
3. Chromatin activation / epigenetic effect - Lezhava 2003 (PMID 14647006): Epitalon decondenses heterochromatin in elderly lymphocytes, reactivating youthful gene transcription patterns.
4. Antioxidant/mitochondrial - raises mitochondrial membrane potential, lowers ROS, increases SOD/catalase in aged tissues (Anisimov 2003).
5. Pleiotropic geroprotection - reduced spontaneous tumor incidence in mice (Anisimov), normalization of glucose/lipid in aged humans, partial reversal of thymic atrophy.

Used for

Healthy aging, telomere/cellular health, sleep quality, circadian rhythm regulation, biological-age management protocols, biohacker stacks.

Pairs well with

• Methylene Blue + Mitomax - full longevity / mitochondrial stack. Epitalon at nuclear/telomere level (long-term blueprint); MB + Mitomax at mitochondrial level (acute bioenergetics). Genomic + bioenergetic axes both addressed. Non-overlapping mechanisms. [Practitioner]
• Synerg Mag - PM sleep stack. Epitalon restores endogenous melatonin via pineal entrainment; Mg cofactor for AANAT, modulates GABA-A, lowers cortisol. Deeper, architecturally more complete sleep (longer N3 + preserved REM). Both 30–60 min pre-sleep. [Clinical (Mg) + Practitioner (combo)]
• BPC + TB4 - included in Muscle Growth & Recovery Stack. Tissue heals predominantly during sleep when GH pulses + protein synthesis + lymphatic clearance peak; Epitalon optimizes the "rest" arm.

Dosing

Haven recommended (label protocol)

• 1 capsule daily (2 mg) at bedtime, oral, with or without food
• Continuous nightly use, or cycle 10–20 nights every 4–6 months (see practitioner notes)
• Always PM - see timing rationale below

Practitioner-directed [Practitioner]

• Khavinson-style cycle (oral approximation): 2–5 caps PM (4–10 mg) × 10–20 consecutive nights, 2–3 cycles/yr, separated by 4–6 months
• Sublingual variant: 1 cap PM held under tongue 60–90 sec - partial buccal absorption may improve uptake
• Continuous low-dose: 1 cap nightly × 30 days, 1–2×/yr (Haven label dose under this framing)
• PM timing rationale: the strongest, most reproducible mechanism is pineal entrainment + melatonin restoration. Dosing 30–60 min pre-bed:

1. Peptide in circulation during natural pineal activation window (AANAT peaks 2–4 hr after sleep onset)
2. Exogenous signal reinforces (rather than competes with) endogenous circadian cues
3. Users report most prominent subjective benefit - improved sleep depth, vivid dreams (REM-density signature), reduced sleep latency

• Why pulsed cycles (10–20 nights, 4–6 mo off): the signal appears to be triggered rather than maintained - once chromatin decondenses and TERT is upregulated, the effect persists. Continuous dosing is not more effective and may attenuate response (theoretical desensitization). The 4–6 month off-period matches lymphocyte telomere turnover timescale.

Cautions / contraindications

• Headache - mild, first 1–3 days, self-limiting (possibly transient vasomotor or melatonin shift)
• Drowsiness - expected, consistent with melatonin restoration. Always PM to avoid daytime sedation.
• Vivid dreams / REM intensification - frequent, usually desirable; rarely problematic
• Paradoxical insomnia - rare (<5% community reports); may indicate dose too high or accidental AM dosing
• Pregnancy / lactation / pediatric - no data, avoid
• Active malignancy - theoretical caution (telomerase activation is a cancer feature) but Khavinson animal data show reduced spontaneous tumor incidence, and human cohort data trended favorably on cancer mortality. Proposed mechanism: AEDG selectively reactivates telomerase in senescent normal cells; transformed cells already have constitutive telomerase, so the AEDG signal is not additive. In active malignancy or pre-cancerous lesions, defer to oncology.
• Endocrine: caution with melatonin agonists (ramelteon, agomelatine) - additive sedation
• Drug interactions: no documented CYP interactions. May potentiate sedatives, benzos, melatonin (additive sleep architecture effect).
• [Caveat] The strongest human longevity evidence is from a single research program (Khavinson + Korkushko, St. Petersburg + Kiev). Independent Western replication of the clinical mortality outcomes does not exist. The in vitro telomerase finding was independently replicated in 2025. Communicate honestly.

Key studies & references

• Khavinson VKh, Morozov VG 2003 - Peptides of pineal & thymus prolong human life - Neuro Endocrinol Lett 24:233 - PMID 14523363 - n=266 elderly, 6–8 yr follow-up, 2–4× mortality reduction in treated vs standard geriatric care
• Korkushko OV et al. 2007 - Bull Exp Biol Med - PMID 17426848 - n=79 coronary patients, 12-yr follow-up, 28% lower all-cause + ~2× lower CV-specific mortality
• Khavinson VKh, Kuznik BI, Trofimova SV 2011 - 15-yr follow-up - Bull Exp Biol Med - PMID 22451889
• Khavinson, Bondarev & Butyugov 2003 - telomerase induction + telomere elongation in human somatic cells - Bull Exp Biol Med 135:590 (foundational mechanism)
• Lezhava T et al. 2003 - Epitalon activates chromatin in old age - PMID 14647006
• Anisimov VN et al. 2003 - Epitalon biomarkers / lifespan / tumors in SHR mice - Biogerontology 4:193 - 12–13% mean lifespan extension in mice
• 2025 replication - Epitalon increases telomere length in human cell lines via telomerase or ALT - Biogerontology DOI 10.1007/s10522-025-10315-x
• MDPI 2025 IJMS review - comprehensive synthesis - PMC11943447

---